Introduction
Polycystic ovary syndrome (PCOS), a heterogeneous disorder that affects up to 10% of women of reproductive age [1] , is characterized by clinical and/or biochemical hyperandrogenism and is frequently accompanied by ovulatory dysfunction and polycystic ovaries [2] . PCOS is considered not only an endocrinopathy that affects reproduction, but is also a metabolic dysfunction: it exhibits several traits characteristic to the metabolic syndrome, manifested through abdominal obesity, insulin resistance, dyslipidemia, endothelial dysfunction and arterial hypertension [3] [4] [5] [6] . Recent data suggest a high cardiovascular risk and an increased prevalence of cardiovascular disease, characterized through impairment of heart structure and function [2, 7] , endothelial dysfunction, lipid abnormalities and a lowgrade chronic inflammation in women with PCOS [2, 3] . The present article reviews the most recent studies that have evaluated vascular abnormalities and inflammatory markers as reliable predictors of subclinical cardiovascular disease in PCOS, as well as the most recent data on the relationship of these markers to insulin resistance, obesity and hyperandrogenemia.
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FMD = flow-mediated dilatation; ET-1 = endothelin-1; sVCAM = soluble vascular cell adhesion molecule; sICAM = soluble intercellular adhesion molecule; PAI-1 = plasminogen activator inhibitor-1; tPA = tissue plasminogen activator; hs-CRP = highly sensitive C reactive protein; TNF-α = tumor necrosis alpha; IL-1 = interleukin 1; IL-6 = interleukin 6; FFA = free fatty acids.
Vascular abnormalities in women with PCOS
Endothelial dysfunction, carotid intimae media thickness (IMT), and arterial calcifications have been regarded as early features of atherosclerosis; their assessment may be a useful tool for detection of preclinical cardiovascular disease. Additionally, accumulating evidence suggests that atherosclerosis represents a chronic inflammatory process that mediates all stages of atherogenesis; thus, evaluation of inflammatory markers represents a good method, albeit indirect, for global assessment of cardiovascular risk.
As actions of the endothelial cells are multiple and involve several systems, alterations in their function may affect one or more of these systems, either simultaneously or at distinct time periods. However, the most commonly accepted dysfunction of endothelial cells is represented by alteration of the regulation of the lumen vessels, defined by blunting of the vasodilatory response to acetylcholine (ACH) or hyperemia. Both of these changes are known to produce nitric oxide (NO)-dependent vasodilation. Endothelial function can be further investigated by measurement of the blood level of selected compounds thought to reflect endothelial cell function, such as endothelin-1 (ET-1), selectin, adhesion molecules, tissue plasminogen activator (t-PA), and plasminogen activator inhibitor-1 (PAI-1). These determinations should be interpreted with caution, since high plasma levels may reflect increased synthesis, decreased clearance, or a combination of both. Therefore, there is no single and standard test to fully assess vascular function and structure in vivo [8] . Table 1 illustrates some of the most frequent tests used for this purpose in clinical research.
Endothelial dysfunction
Endothelial dysfunction is known to be the initiating event in the development of atherogenesis [9, 10] . The healthy endothelium, in particular endothelium-derived NO, modulates the tone of underlying vascular smooth muscle and participates in processes that are beneficial to the vasculature. It inhibits several pro-atherogenic pathways, including vascular smooth muscle cell migration and growth, oxidation of LDLs, monocyte and macrophage adhesion, platelet aggregation and thrombosis, synthesis of inflammatory cytokines [3, 9] . Nitric oxide opposes the actions of potent endotheliumderived contracting factors such as angiotensin II and ET-1. Besides being a very potent vasoconstrictor, ET-1 augments the vascular actions of other vasoactive peptides such as angiotensin-II, norepinephrine, and serotonin; it also participates actively in leukocyte and platelet activation and facilitates a pro-thrombotic and pro-atherogenic phenotype [11] . A balanced release of endothelial bioactive factors facilitates vascular homeostasis; endothelial dysfunction can be defined as the partial or complete loss of this state of equilibrium [12] .
2.1.a. Studies of Vasomotion
The assessment of blood flow and vascular reactivity allows the investigator to evaluate the status of endothelial cells as well as that of underlying vascular smooth muscle cells. Endothelial function of both conduit and resistance arteries is the surrogate cardiovascular endpoint most widely studied in PCOS.
Macro-vascular endothelial function (conduit arteries)
Measurement of post-ischemic flow-mediated dilatation (FMD) of the brachial artery with high resolution ultrasonography is an established method of assessing endothelial function of conduit arteries; it correlates with measures of coronary endothelial dysfunction [10] . Studies performed in women with PCOS show impaired endothelium-dependent FMD or endotheliumindependent, glyceroltrinitrate-mediated dilatation (GTN-MD) vascular responses of the brachial artery [3, [13] [14] [15] and that impaired FMD was associated with insulin resistance, total cholesterol and C-reactive protein (CRP) levels; relationship to testosterone levels was controversial [1, 3, 13] . In subsequent research, Tarkun et al found a significant improvement in insulin resistance, endothelium-dependent vascular responses, and a decrease in the level of testosterone and CRP after rosiglitazone treatment [16] . Recently, Sorensen et al. [17] accurately measured endothelium-dependent and independent arterial reactivity by cardiovascular magnetic resonance (CMR) in a group of women with PCOS. They demonstrated that PCOS is associated with pronounced endothelial dysfunction, but contrary to the results of another study by Kravariti et al., impairment in vasodilatation was specific to endothelium-dependent vasodilatation and was not observed in response to GTN, a nonspecific vasodilator.
Micro-vascular endothelial function (resistance arteries)
Endothelial dysfunction of the microcirculation and resistance vessels in PCOS has also been examined by invasive studies employing intra-arterial infusion of vasoactive agents with thermodilutional or plethysmographic assessment of limb blood flow. In a study by Paradisi et al., leg blood flow (LBF) was measured by means of an intravenous thermodilution catheter in a group of obese women with PCOS showing impaired LBF responses to methacoline and to hyperinsulinemia during a euglycaemic clamp, compared with a control group. However, it should be mentioned that LBF response to sodium nitroprusside, an endothelium independent vasodilator, was not assessed, meaning that the demonstrated defect could not necessarily be localized to the endothelial cell as opposed to smooth muscle. Impaired endotheliumdependent vasodilatation was related to both androgen levels and insulin resistance [18] . Using the same techniques, an improvement in the endothelial dysfunction was noted after 3 months of treatment with rosiglitazone in PCOS subjects compared with controls; this improvement was associated with a decrease in insulin resistance, testosterone and PAI-1 level [19] . An ex vivo study measured the contractile response of gluteal resistance arteries to norepinephrine before and after incubation with insulin, thus confirming the above results, namely, that there is a resistance to the vasodilator effects of insulin in PCOS [20] , which proved to be present even in the absence of other risk factors. The defect in the resistance arterioles revealed in that study appears to be specific to the action of insulin, since constriction to norepinephrine and relaxation to ACH were not different between the PCOS group and the control group. In contrast, Bickerton et al, using venous occlusion plethysmography to assess differences in reactive hyperemia of the forearm microcirculation, found no evidence of endothelial dysfunction in women with PCOS compared with age-and weight-matched controls without PCOS [21] . Carmassi et al., who studied PCOS women with and without insulin resistance, demonstrated a blunted vasodilatory response to insulin and an abolished expression of t-PA exclusively in insulin-resistant patients, suggesting that insulin resistance rather than PCOS status confers endothelial dysfunction in this vascular bed [22] . Overall, data resulting from studies of conduit arteries support the presence of endothelial dysfunction in women with PCOS and a link to insulin resistance. Similarly, studies of resistance arteries point to the presence of endothelial dysfunction in different arterial beds in PCOS, which is associated with insulin resistance and less consistently with hyperandrogenemia. The slight differences among results obtained in studies might be explained either through the different methodology used for the investigation of vascular reactivity and endothelial dysfunction, or through the different metabolic status of the recruited patients. For example, in the study by Paradisi et al, leg blood flow was measured by means of an intravenous thermodilution catheter, considered the gold standard technique [8] , and whole-body glucose disposal was assessed with the euglycemic hyperinsulinemic clamp technique. Bickerton et al. used venous occlusion plethysmography, which only weekly correlates with the gold standard technique and is very dependent upon local expertise [8] . Moreover, the insulin sensitivity was not measured directly, so it might be possible that both the PCOS group and control group displayed an Vascular abnormalities and low-grade chronic inflammation in women with polycystic ovary syndrome: Relationships with insulin resistance, obesity and hyperandrogenemia insignificant degree of insulin resistance, or none at all. And, as so fa insulin resistance appears to be the major responsible factor related to endothelial dysfunction as reflected by altered vascular reactivity, the lack of insulin resistance and of a difference in the metabolic status between the PCOS subjects and controls might contribute to the absence of any difference in reactive hyperemia, or any of the biochemical parameters used to assess atherothrombosis risk in this study, in women with PCOS compared with age-and weight-matched controls. This seems to be confirmed by the results of Carmassi et al, in whose study insulin-sensitive PCOS patients showed a profile of vasodilatation and t-PA release upon insulin infusion similar to that of controls, who were, of course, insulin-sensitive.
2.2.b. Biomarkers of endothelial dysfunction
In healthy vessels, an infusion of an endotheliumdependent vasodilatator, such as acetylcholine, induces a NO-mediated vasodilatory response; however, in patients with endothelial dysfunction, this effect is blunted, or paradoxical vasoconstriction may occur [23] .
There are very few studies that have assessed the level of NO in PCOS patients. To the best of our knowledge, only Nacul et al evaluated the concentration of nitrite/ nitrate (index of endothelium-derived NO) in a PCOS group compared to an age-matched control group and found similar levels of nitrite/nitrate and fibrinogen in the two groups. A negative body mass index (BMI)-independent correlation between NO and insulin resistance was seen only in PCOS patients, but no association was observed between NO and BMI, waist circumference, or waist-hip-ratio (WHR), suggesting that in PCOS endothelial dysfunction is related to the presence of insulin resistance rather than to obesity per se. In addition, NO was not correlated with androgens in either the PCOS group or the control group [24] . Endothelin-1 has endothelial mitogenic effects [25] and seems to play a role in the early events of endothelial dysfunction. Therefore, it can be used as a marker of abnormal vascular reactivity. Diamanti-Kandarakis et al were the first to demonstrate elevated ET-1 levels in PCOS compared with controls. A positive correlation of ET-1 with free T levels was shown, as well as a negative correlation of ET-1 with glucose utilization, that might indicate an involvement of hyperinsulinemia and insulin resistance in the abnormal endothelial status [26] . It appears that early impairment of endothelial structure and function is present even in young women with PCOS, as suggested by significantly higher ET-1 levels in normalweight, non-dyslipidemic, and non-hypertensive women with PCOS than in BMI-matched healthy controls [14] . Metformin therapy appeared to have beneficial effects, decreasing ET-1 levels [26, 27] ; the mechanism by which metformin acts to improve endothelial dysfunction is still unclear, although suppressive effects on circulating androgens and insulin and improvement in insulin sensitivity are probably important components [27] .
Morphological studies
Two major anatomic markers for subclinical cardiovascular disease are carotid intimae mediathickness (CIMT) assessed by ultrasonography or angiography, and coronary artery calcifications (CAC) evaluated by electron-beam tomography [4] . Significantly higher CIMT values were reported in PCOS subjects aged ≥45 years compared to controls [28] , and in young, normal weight PCOS women compared with controls [29] . Increased CIMT was found to be related to insulin resistance [28, 30] and lower adiponectin levels [30] or to correlate with free androgen index [14] , thus suggesting a contribution of hyperandrogenemia to progression of atherosclerosis in PCOS. Coronary artery calcifications, which are both radiographic markers for coronary atherosclerotic plaque and predictors of clinical events, were found more prevalent in premenopausal obese women with PCOS aged 30-45 years in comparison to controls [31] . In a nine year follow-up study, an increased incidence of CAC was described in middle-aged women with PCOS; the degree of calcification was dependent on central obesity, elevated blood pressure, dyslipidemia, and thus insulin resistance [32] . These reports suggest that women with PCOS have morphological evidence of coronary atherosclerosis, and that insulin resistance in particular is the major causal factor. While the morphological changes in the vascular wall seem to be more evident in middle-aged and older women with PCOS, endothelial dysfunction is more likely a feature of the vasculopathy of young women with PCOS. This is not surprising, since endothelial dysfunction has been shown to occur earlier in the atherosclerosis development and progression, preceding the onset of increased CIMT [10, 33] .
Indices of low-grade chronic inflammation
Adipose tissue represents an important source of pro-inflammatory mediators, including tumor necrosis factor (TNF-α), interleukin-6 (IL-6), interleukin-18 (IL-18) and procalcitonin (PCT) [34] [35] [36] [37] [38] . Elevated levels of inflammatory markers, particularly C-reactive protein, indicate an increased risk of coronary heart disease [39] , although some authors suggest that this predictive value of CRP should be reviewed [40] . Vascular inflammation plays a pivotal role in atherosclerotic lesion formation, progression, and eventual rupture. Chronic inflammation results in endothelial dysfunction [23] . Additionally, proinflammatory cytokines such as IL-6, TNF-α, TNF-soluble receptors, and IL-18 are among several important factors that participate in the development of insulin resistance, type 2 DM, and cardiovascular disease [41] [42] [43] [44] .
C-reactive protein
Recent data suggests that CRP is not only an inflammatory marker for atherosclerosis, but it may have some directly deleterious effects on the vascular wall, promoting endothelial dysfunction by increasing expression of endothelial cell adhesion molecules (CAMs), monocyte chemo-attractant protein (MCP)-1 secretion, and macrophage LDL-uptake [23] . It appears that CRP directly influences production of endotheliumderived vasoactive factors: it decreases NO production while augmenting production of the ET-1, promotes the release of PAI-1 from endothelial cells [45] , and upregulates angiogenesis-mediated neointimal formation [46] . Additionally, CRP facilitates endothelial cell apoptosis and attenuates angiogenesis [23] . Increased serum CRP levels were found in obese and non-obese PCOS compared to controls [3, [47] [48] [49] , with significantly higher values in obese than in non-obese PCOS subjects [50] that decreased after treatment with metformin [50] or rosiglitazone [16] . Serum CRP was positively related to BMI [3, 47, 50] and insulin resistance [3, 47] , and to a lesser extent to WHR, suggesting that the elevated CRP levels may be related mainly to obesity and not to PCOS itself. More recently, Diamanti-Kandarakis et al demonstrated once again that women with PCOS display higher serum CRP levels compared to controls, with BMI as the only predictor of CRP levels. [51] Those authors also studied the coexistence of active inflammation markers and endothelial dysfunction, and their relationship to metabolic and hormonal abnormalities of the syndrome. Serum CRP concentrations were positively related to BMI, but negatively related to FMD values and insulin sensitivity indices. Furthermore, FMD was statistically higher in the PCOS population (CRP ≤1mg -1 ) when compared with the PCOS population (CRP ≥1mg -1 ). The finding that increased levels of CRP are consistent with the severity of endothelial dysfunction supports the hypothesis that chronic inflammation contributes to endothelial dysfunction [52] .
Hyperleukocytosis as marker of low-grade chronic inflammation in PCOS
An elevated white blood cell (WBC) count is a risk factor for atherosclerotic vascular disease, and is present in adult women with genetic predisposition to type 2 diabetes mellitus (DM). An increased leukocyte count was found in women with PCOS compared to the control group [49] ; it was detectable already at a young age [53] ; insulin resistance was probably the main factor responsible for this finding [49] . Analyzing the leukocyte formula, a significant rise in lymphocytes and monocytes [49] or neutrophils [53] in PCOS subjects versus controls was noted. Metformin and the combination flutamide-metformin had a beneficial effect on low-grade inflammation, attenuating WBC [54] and hyperneutrophilia [53] , which suggests a link between hyperleukocytosis and insulin resistance.
Inflammatory cytokines
An increased flow of substances, cytokines and hormones from insulin-resistant adipose tissue to the skeletal muscle, liver, and the endothelium play a crucial role in affecting glucose metabolism and vascular function. Free fatty acids (FFAs) and TNF-α impair insulin action at the level of the peripheral tissues; they also appear to have some direct effect on the vasculature, causing endothelial dysfunction [55, 56] . FFAs seem to be closely linked with impaired vascular reactivity, which is a measure of endothelial dysfunction [55] . TNF-α promotes the synthesis of IL-6, a recognized mediator of insulin resistance that regulates the synthesis of CRP in the liver. Both IL-1 and IL-6 are elevated in obesity and insulin resistance, and have found to be closely related to endothelial dysfunction and sub-clinical inflammation [41, 56] . Other researchers have found increased levels of serum TNF-α in normal-weight women with PCOS, and even higher concentrations in obese individuals regardless of the presence of PCOS, suggesting that factors other than obesity are the cause of elevated serum TNF-α in normal-weight women with PCOS [57] . Of note, mean serum TNF-α concentrations in obese women with PCOS and obese controls were similar. However, there are studies that have not confirmed the elevated levels of cytokines. Plasma IL-6 and CRP concentrations were not found to be significantly different between PCOS and healthy control women. However, after dichotomizing the cohort at a BMI of 25 kg/m 2 , they were significantly increased in both obese PCOS and obese control women as compared with their lean counterparts. In PCOS patients, variables of body composition (BMI, WHR, fat mass) and insulin resistance were correlated with IL-6 or CRP, with the Vascular abnormalities and low-grade chronic inflammation in women with polycystic ovary syndrome: Relationships with insulin resistance, obesity and hyperandrogenemia BMI the parameter most strongly related to these variables, while parameters of hyperandrogenism were not. Since PCOS-related endocrine abnormalities, such as hyperandrogenemia, do not seem to activate inflammatory parameters, PCOS per se appears not to be associated with increased chronic inflammation [58] . That observation is sustained by a more recent study by Olszanecka-Glinianowicz et al; no differences were observed in serum concentrations of TNF-α between obese patients with PCOS and obese subjects without additional disease [42] . A novel finding in this study was that despite the lack of differences in serum concentrations of TNF-α, and in contrast with the study by Mohling et al [58] , the levels of IL-6 were lower in obese patients with PCOS compared with obese women without additional disease [42] . Since there is no explanation for these findings at present, further studies are necessary to clarify the presence of chronic inflammation, reflected as an increased level of cytokines in PCOS. Overall, we conclude that if PCOS were characterized by an elevated level of cytokines, the latter might be accounted for by obesity rather than PCOS status.
Markers of endothelial activation
Cell adhesion molecules are expressed on the surface of endothelial cells and leukocytes in response to endothelial dysfunction in order to control the complicated process of leukocyte rolling, adhesion, and transmigration into the sub-intimal space. Elevated serum levels of adhesion molecules, intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1) and sE-selectin reflect low-grade chronic inflammation of the endothelium and predict the risk for CHD and type 2 DM [11, 57] . Recently, Diamanti-Kandarakis demonstrated increased levels of inflammatory markers -CRP, Sicam-1, and sE-selectin [51] , and sVCAM-1 [52] in women with PCOS with beneficial effects of metformin therapy on CRP and sVCAM-1 levels. That result suggests the presence of a pro-atherogenic state in young women with PCOS [51] . The relationship between hyperandrogenemia and inflammation is under investigation.
Procalcitonin
Puder et al were first to evaluate the level of PCT in women with obesity and PCOS and also the effect of body fat distribution (i.e., central fat accumulation) on inflammatory markers. PCT levels correlated significantly with both body fat and body fat distribution; thus, PCT seems to represent a novel marker of the more chronic inflammatory activity of body fat and of PCOS [59] . In aggregate, these data of inflammatory markers in PCOS point to the presence of low-grade chronic inflammation in women with PCOS. The majority of studies have shown that the association of inflammatory markers with PCOS is mainly dependent upon co-existent obesity and insulin resistance. The increased level of CRP or TNF-α present in normal-weight women with PCOS compared with BMI-matched controls found by some authors might be related to increased abdominal adiposity, which was insufficiently assessed in some studies.
Relationship of endothelial dysfunction and low-grade chronic inflammation with insulin resistance in PCOS
The data from literature point to the early presence of endothelial dysfunction and low-grade chronic inflammation in women with PCOS, suggesting that they might develop cardiovascular disease early, and that even very young and non-obese patients are at risk. The evidence, based solely on association studies to date, indicates that insulin resistance and obesity may be the mediators of early endothelial dysfunction, both carotid and coronary atherosclerosis, and chronic inflammation.
The presence of insulin receptors on endothelial cells is well documented, and the endothelium is now considered as a potentially important target for insulin, with insulinstimulated production of NO, a feature of the direct action of insulin on endothelial cells. A number of studies have demonstrated a close association between insulin resistance and NO bioactivity [60] . Insulin stimulates NO production in endothelial cells and glucose uptake in muscle and fat tissue through the activation of phosphatidylinositol 3-kinase (PI-3K) and Akt pathway, while other effects of insulin action on the vasculature, including the stimulation of migration and growth of smooth muscle cells and the production of PAI-1 are mediated through the mitogen-activated protein kinase (MAPK) pathway. In theory, insulin-resistant individuals might have a partial block to insulin action through the PI3K pathway in skeletal muscle and endothelial cells, with an intact MAPK pathway (as it has been described in Zucker rats) that could partially explain the proatherogenic state and their increased cardiovascular risk [56] . Insulin might also regulate endothelial NO synthase (eNOS) transcription in endothelial cells [60] . Beside this, stoichiometric imbalance between L-arginine, NADPH and tetrahydrobiopterin (BH4) induces uncoupling of eNOS, impairing synthesis of NO. Tetrahydrobiopterin is a critical cofactor for eNOS activation. Of outmost importance, in the setting of BH4 deficiency activation of eNOS leads to uncoupling of NOS with subsequent generation of super oxide anion and hydrogen peroxide and peroxynitrite [61] . The rate-limiting enzyme in BH4 biosynthesis is GTP-cyclohydrolase (GTPCH)-1; there is evidence that supports a role for insulin in upregulation of GTPCH-1, stimulating BH4 synthesis. In insulin resistant states these effects are impaired [62] . Furthermore, BH4 itself is rapidly degraded by reactive oxygen species (ROS) such as superoxide, so that a vicious cycle can ensue, whereby oxidative stress worsens BH4 deficiency [60] . Many other abnormalities may certainly contribute to the link between insulin resistance and endothelial dysfunction, including the production of ROS, inflammation and cytokines such as TNF-α, activation of the renin-angiotensin system [63, 64] , and elevation of ET-1 [65] . Insulin resistance and obesity are also frequently associated with other traditional cardiovascular risk factors such as type 2 DM, hypertension, dyslipidemia, and altered coagulation/ fibrinolysis, all components of the metabolic syndrome that act to create a state of constant and progressive damage to the vascular wall, manifested by a low-grade progressive inflammatory process and endothelial dysfunction [9] . The latest studies strongly support the hypothesis that endothelial dysfunction leads to insulin resistance, suggesting a reciprocal relationship between endothelial dysfunction and insulin resistance [66] . It has been suggested that insulin-mediated vasodilatation and capillary recruitment contribute to glucose uptake by increasing delivery to skeletal muscle. Therefore, a state of endothelial dysfunction would limit the ability of insulin to reach its target organ and to produce its metabolic effects [9, 60] .
Role of hyperandrogenemia in endothelial dysfunction and lowgrade chronic inflammation in PCOS
The contribution of hyperandrogenemia to endothelial dysfunction or chronic inflammation remains unclear and controversial, and conflicting results have been reported in both female and male populations. Higher cardiovascular morbidity and mortality in men than in women of similar age was formerly often attributed to the sex difference in circulating testosterone levels, but recent studies in men suggest that low rather than high endogenous androgen levels are related to coronary heart disease [67] . Among women, some studies have suggested an adverse effect of testosterone on endothelial function [14, 18, 32, 52] , while others were not able to prove any significant correlation with the various markers of endothelial injury in women with PCOS [33, 68, 69] . On the other hand, there have been reports that showed a protective effect in patients with PCOS [10] as well as in women at postmenopause [70] . As the mechanisms of action, high testosterone levels have been found to increase TNF-α-induced VCAM-1 and E-selectin expression in endothelial cells [71, 72] , and dihydrotestosterone has also been shown to promote monocyte adhesion to endothelial cells in the development of atherosclerosis, an effect mediated at least in part by an increased endothelial cell-surface expression of VCAM-1, through an NF-κB-dependent mechanism [73] . The effects of androgen administration to female-to-male transsexuals may serve as a model of long standing hyperandrogenenism in women, providing important information regarding the potential negative effects on cardiovascular risk factors associated with high levels of androgens. The only drawback of this model is the sometimes relatively short period of evaluation accompanying the therapy with testosterone, probably insufficient for androgens to carry out some of their effects. Studies on female-to-male transsexuals receiving high doses of testosterone showed that this supraphysiological testosterone administration was associated with an increase in weight, visceral fat, triglycerides, ET-1, CRP, as well as total homocysteine, and a decrease in high-density lipoprotein cholesterol and LDL-particle size [74, 75] and adiponectin levels [76] or impaired vascular reactivity [77] . But while these markers of cardiovascular risk factors demonstrated a shift to a more negative risk profile, others were not affected by androgen administration: no significant change was noted in blood pressure, fibrinolytic markers (PAI-1, t-PA), arterial stiffness, fibrinogen, IL-6 [74] , and insulin sensitivity [74] [75] [76] . All in all, these reports suggest that androgen effects on cardiovascular risk markers are therefore not unequivocally and universally negative. Thus, it is reasonable to assume that, taking into account that, on the one hand women with PCOS have androgenic levels lower than those administered for sex reassignment in female-to-male transsexuals and, on the other hand, women in general, demonstrate a smaller androgen receptor expression on endothelial cells, relative to male endothelial cells [73] , women with PCOS will be even less negatively affected with respect to cardiovascular risk. Moreover, some reports showed that increased CIMT was inversely correlated with plasma DHEAS [10, 68] and androstendione [68] levels, while the duration of reactive hyperemia as assessed by venous occlusion plethysmography was positively related to DHEAS levels Vascular abnormalities and low-grade chronic inflammation in women with polycystic ovary syndrome: Relationships with insulin resistance, obesity and hyperandrogenemia in PCOS, but without a significant association with HOMA-IR index [69] , suggesting an intriguing vasculo-and cardio-protective effect of hyperandrogenemia in PCOS. This effect might counterbalance in part the adverse effect of cardiovascular risk factors, such as insulin resistance that accompany PCOS. As the underlying mechanism, it was postulated that DHEAS may directly induce endothelial NO synthesis through a genomic mechanism-via enhanced expression and stabilization of endothelial nitric oxide synthase (eNOS)-and also through a non-genomic, acute enhancement of its activity, human endothelial cells being characterized as primary targets for DHEAS [78] . However, it is important to note that other investigators who studied the possible association of endothelial function with DHEAS found no relationship [10, 14, 18, 33] . Similar to other steroids, including estrogen, vitamin D, and progesterone, for which, besides their known intracellular receptors, functional plasma membrane binding sites, whose non-genomic actions the latter are postulated to modulate, have been identified, the presence of a putative receptor for DHEA on vascular cells has been suggested by recent reports [79, 80] . Liu and Dillon demonstrated for the first time the presence of a high affinity, specific DHEA plasma membrane receptor on bovine aorthic endothelial cells [80] and later also on human endothelial cells [81] , and that this receptor is functionally coupled to the Gi protein and primarily to Gαi2 and Gαi3 subtypes. Activation of these G-proteins mediates the effect of DHEA on eNOS [80] . In line with these data, a recent study concluded that DHEA has acute, specific non-genomic actions in the endothelium, which mimic vascular actions of insulin to stimulate production of the vasodilator NO via PI 3-kinase-dependent pathways and secretion of the vasoconstrictor ET-1 via MAPK-dependent pathway. The authors suggest that altering the balance between PI 3-kinase-and MAPK-dependent signaling in vascular endothelium may determine whether DHEA has beneficial or, to the contrary, harmful, prohypertensive and proatherogenic effects on endothelium. These findings may also explain conflicting reports regarding putative beneficial effects of DHEA on metabolic and cardiovascular health in humans [82] .
Relationship of obesity/central adiposity with endothelial injury
Accumulation of visceral fat leads to insulin resistance, endothelial dysfunction and a proinflammatory status through fat-derived metabolic products, hormones, and cytokines: it has been shown that patients with PCOS had an excess of central fat independent of total fat mass [59, 83] . In particular, low levels of adiponectin, an adipokine secreted exclusively by adipocytes, are involved in the development of insulin resistance. Low plasma concentrations of adiponectin have been observed in obesity, type 2 DM, and coronary artery disease [84] . Interestingly, adiponectin also has vascular actions that stimulate the production of NO in endothelium, and has antiatherogenic and anti-inflammatory properties [66] . Ouadraogo et al have demonstrated that adiponectin deficiency increases leukocyte rolling and leukocyte adhesion to endothelium via reduced availability of eNO at the vascular wall and up-regulation of endothelial CAMs that are relevant to vascular inflammation and atherosclerosis [85] . The majority of studies performed on women with PCOS demonstrate a decreased level of adiponectin compared to controls [30, 86, 87] . Plasma adiponectin levels correlated negatively with WHR and positively with glucose disposal rate in a group of nonobese PCOS women, with waist circumference as the best predictor of adiponectin level, suggesting that adiponectin has a role in the regulation of insulin resistance and that it is a good indicator of abdominal fat mass [88] . Supporting these observations, it has been shown that hypoadiponectinemia is present in PCOS independent of BMI, with WHR [86] , waist circumference [89] , and free testosterone levels [86] as the major determinants of decreased concentrations of adiponectin. These studies suggest that abdominal adiposity is characteristically associated with hypoadiponectinemia; hyperandrogenemia may also have a role, probably by facilitating an abdominal deposition of fat, as mentioned further in the study. A negative correlation was found by Carmina et al between levels of adiponectin and IMT in a PCOS group compared with matched controls, which was unchanged when adjusting for BMI or by insulin resistance parameters, suggesting that the decrease in adiponectin may be an independent risk factor, in addition to insulin resistance, for the development of endothelial damage in PCOS [30] . The authors could not find a correlation between WHR, which was similar in women with PCOS and controls, and adiponectin in that report. However, as they also mentioned, WHR is an imprecise measure of visceral obesity, so an increase in central obesity in PCOS women from their study cannot be totally ruled out. Finally, Bik et al did not find a significant difference between levels of adiponectin in lean subjects with PCOS compared to lean healthy women, although the PCOS group demonstrated a tendency to lower adiponectin level [90] . In any case, it should be mentioned that the groups were not significantly different as far as WHR was concerned and they did not carry out direct measurements of fat and lean body mass and of body fat distribution by scan, so it is possible that the lack of a significant difference in adiponectin levels might have derived from the absence of differences in the distribution of body fat in the groups of women compared in their study. Although these reports have some limitations related to the methodology or the how body fat mass was assessed, the data presented here support the relationship between excess abdominal adiposity and hypoadiponectinemia. Aside from the well-established role of insulin resistance and hyperinsulinemia as facilitating factors for androgen excess, molecules secreted by adipose tissue such as leptin, TNF-α, and IL-6 might also influence adrenal and ovarian function. Mounting evidence suggests that androgen excess influences the predominantly visceral disposition of body fat in PCOS women [91] , hence a vicious circle in which androgen excess determines abdominal adiposity and visceral fat facilitates further androgen excess [91] . Figure 1 illustrates a hypothesis for the pathogenesis of endothelial dysfunction in PCOS and the potential pathways through which cardiovascular risk factors associated with PCOS may contribute to endothelial injury development and implicit to cardiovascular disease, and the numerous and complex mechanisms by which they are interrelated.
Conclusions
Our present research is in favour of the presence of vascular injury and chronic low-grade inflammation in women with PCOS. Although PCOS is increasingly recognised not only as being associated with a clustering of major cardiovascular risk factors, but also provides evidence of sub-clinical cardiovascular diseases, reliable clinical end-point data on cardiovascular disease can not be predicted. Consequently, there is still controversy on the likelihood of increased cardiovascular events in women with PCOS. This is due to the lack of long-term outcome studies on cardiovascular events and mortality. Thus, there is a need for longitudinal, prospective, casecontrol, more rigorous, large sample size studies in young women with PCOS, all of which should be not only long term so as to go beyond menopause but also homogeneous in terms of both prevalence and degree of obesity. Future studies should also be consistent in terms of the methodology used for evaluating vascular injury in order to document the early presence of vascular abnormalities and chronic inflammation, and to establish whether these cardiovascular risk factors subsequently lead to cardiovascular events. Discrepancies among some studies may be due to small sample sizes, bias in case-control designs and use of non-standard definitions of PCOS. There is a need for a better evaluation of the role of the major risk factors, including insulin resistance, visceral obesity, and hyperandrogenaemia in the pathogenesis of endothelial dysfunction in PCOS. Similarly, studies that should clarify the deleterious or beneficial effect of the androgens-DHEAS and specially testosterone-are warranted. These findings might also be important from the medical management point of view, since the oral contraceptive pill, aimed primarily at lowering serum androgens while potentially increasing insulin resistance and ineffective in attenuating abnormal Vascular abnormalities and low-grade chronic inflammation in women with polycystic ovary syndrome: Relationships with insulin resistance, obesity and hyperandrogenemia adipocytokine levels and body adiposity [83] , may have adverse effects on long term cardiovascular risk. On the other hand, based on the studies we suggest the definition of PCOS might be reconsidered, and metabolic criteria such as insulin resistance, which seems to play the central role in the endocrine and metabolic aspects of PCOS, should be considered. Thus, particular subtypes, specially the ones with a particular adverse metabolic phenotype that supposes a cardiovascular risk, might receive special attention and further evaluation.
